Allogeneic (off-the-shelf) cell therapy
Cell therapies made from healthy donors in advance, so patients do not have to wait for their own cells to be engineered.
Gene-edited donor T cells (Allogene cema-cel, ALLO-316 CD70; Caribou; CRISPR Therapeutics) remove TCR and HLA to avoid rejection. Persistence is the main limitation. Also iPSC-derived platforms (Fate, Century).
How it works
TRAC knockout prevents GVHD; B2M/HLA editing or CD52 knockout with alemtuzumab conditioning delays host rejection.
- Immediate availability, industrial scale
- Host rejection limits persistence
- Deeper lymphodepletion
Latest papers
topQuery for this technology: (TITLE:"allogeneic CAR T" OR ABSTRACT:"allogeneic CAR T" OR TITLE:"off-the-shelf CAR T" OR ABSTRACT:"off-the-shelf CAR T" OR TITLE:"allogeneic CAR-T" OR ABSTRACT:"allogeneic CAR-T"). Results are unfiltered search hits about Allogeneic (off-the-shelf) cell therapy, not a curated reading list.
Pages like this
not linked directly; found by shared links- CancerAcute lymphoblastic leukaemia
Shares CD7, Stephen J. Forman, Masonic Cancer Center, University of Minnesota, Ramathibodi Hospital, Mahidol University.
- TechnologyGlobal oncology and access in low- and middle-income countries
Shares Christian Medical College, Vellore, National Cancer Institute, Cairo University, Tata Medical Center, Kolkata, Charlotte Maxeke Johannesburg Academic Hospital / University of the Witwatersrand.
- CancerDiffuse large B-cell lymphoma
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, Stephen J. Forman, Caribou Biosciences, Sana Biotechnology.
- TechnologyIn vivo CAR-T
Shares Hans-Peter Kiem, Sana Biotechnology, UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL, Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR.
- TechnologyAllogeneic donor and iPSC master cell banks
Shares Caribou Biosciences, UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL, CAR-NK & CAR-macrophage, CAR-T cell therapy.
- CompanyNkarta
Shares Off-the-shelf natural killer cells to sweep up residual disease, CAR-NK & CAR-macrophage, CD19, Acute myeloid leukaemia.
- TechnologyGermline (hereditary) testing
Shares Hamad Medical Corporation / National Center for Cancer Care and Research, Ramathibodi Hospital, Mahidol University, Hospital Universitari i Politècnic La Fe, King Faisal Specialist Hospital and Research Centre.
- TechnologyIMRT / IGRT (modern external beam)
Shares Hamad Medical Corporation / National Center for Cancer Care and Research, Tawam Hospital, Comprehensive Cancer Center Freiburg (CCCF), National Cancer Institute, Cairo University.